This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press released include predictions regarding the sufficiency of current cash and cash equivalents to fund operations for 12 months or more, intent to submit a revised CLIA waiver application, building sales in Europe and Canada, seeking CLIA waiver and Medicare reimbursement, and the future commercial adoption of the TearLab(tm) Osmolarity System. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Kilmer Lucas Inc.         Stephen Kilmer (President)         905 690-2400 Ext.21         stephen@kilmerlucas.com         Kilmer Lucas Inc.         Leonard Zehr (Managing Director)         905 690 2400 Ext.41         len@kilmerlucas.com

If you liked this article you might like

Insider Trading Alert - TEAR, AMSF And DLTR Traded By Insiders

5 Breakout Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Sell These 7 Health Care Supplies Companies Now

Insider Trading Alert - RPTP, TEAR And ISRG Traded By Insiders